TYSON FOODS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TYSON FOODS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $54.44B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $53.31B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $52.88B | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $53.28B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $47.05B | Nov 13, 2023 |
| FY2020 | Oct 3, 2020 | $11.46B | Feb 11, 2021 |
| FY2020 | Jun 27, 2020 | $10.02B | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | $10.89B | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | $10.82B | Feb 11, 2021 |
| FY2020 | Sep 28, 2019 | $10.88B | Feb 11, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $54.44B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $53.31B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $52.88B | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $53.28B | Nov 12, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $10.15B | Nov 13, 2017 |
| FY2017 | Jul 1, 2017 | $9.85B | Nov 13, 2017 |
| FY2017 | Apr 1, 2017 | $9.08B | Nov 13, 2017 |
| FY2017 | Dec 31, 2016 | $9.18B | Nov 13, 2017 |
| FY2017 | Oct 1, 2016 | $9.16B | Nov 13, 2017 |
| FY2017 | Jul 2, 2016 | $9.40B | Nov 13, 2017 |
| FY2017 | Apr 2, 2016 | $9.17B | Nov 13, 2017 |
| FY2017 | Jan 2, 2016 | $9.15B | Nov 13, 2017 |
| FY2016 | Oct 3, 2015 | $10.51B | Nov 21, 2016 |
| FY2016 | Jun 27, 2015 | $10.07B | Nov 21, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $3.56B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $3.63B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $2.63B | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $6.67B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $6.53B | Nov 13, 2023 |
| FY2020 | Oct 3, 2020 | $1.61B | Feb 11, 2021 |
| FY2020 | Jun 27, 2020 | $1.31B | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | $1.02B | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | $1.44B | Feb 11, 2021 |
| FY2020 | Sep 28, 2019 | $1.14B | Feb 11, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $474.00M | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $800.00M | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | ($648.00M) | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $3.24B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $3.05B | Nov 13, 2023 |
| FY2020 | Oct 3, 2020 | $654.00M | Feb 11, 2021 |
| FY2020 | Jun 27, 2020 | $526.00M | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | $376.00M | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | $505.00M | Feb 11, 2021 |
| FY2020 | Sep 28, 2019 | $372.00M | Feb 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $1.10B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $1.41B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | ($395.00M) | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $4.41B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $4.40B | Nov 13, 2023 |
| FY2020 | Oct 3, 2020 | $962.00M | Feb 11, 2021 |
| FY2020 | Jun 27, 2020 | $773.00M | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | $515.00M | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | $758.00M | Feb 11, 2021 |
| FY2020 | Sep 28, 2019 | $608.00M | Feb 11, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $126.00M | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $106.00M | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $114.00M | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $108.00M | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $114.00M | Nov 13, 2023 |
| FY2022 | Oct 3, 2020 | $98.00M | Nov 14, 2022 |
| FY2021 | Sep 28, 2019 | $97.00M | Nov 15, 2021 |
| FY2020 | Sep 29, 2018 | $114.00M | Feb 11, 2021 |
| FY2019 | Sep 30, 2017 | $113.00M | Nov 12, 2019 |
| FY2018 | Oct 1, 2016 | $96.00M | Nov 13, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $2.12B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $2.22B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $2.25B | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $2.26B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $2.13B | Nov 13, 2023 |
| FY2020 | Oct 3, 2020 | $648.00M | Feb 11, 2021 |
| FY2020 | Jun 27, 2020 | $540.00M | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | $506.00M | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | $682.00M | Feb 11, 2021 |
| FY2020 | Sep 28, 2019 | $531.00M | Feb 11, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $2.16B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $2.59B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $1.75B | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $2.69B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $3.84B | Nov 13, 2023 |
| FY2022 | Oct 3, 2020 | $3.87B | Nov 14, 2022 |
| FY2021 | Sep 28, 2019 | $2.51B | Nov 15, 2021 |
| FY2020 | Sep 29, 2018 | $2.96B | Feb 11, 2021 |
| FY2019 | Sep 30, 2017 | $2.60B | Nov 12, 2019 |
| FY2018 | Oct 1, 2016 | $2.72B | Nov 13, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $978.00M | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $1.13B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $1.94B | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $1.89B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $1.21B | Nov 13, 2023 |
| FY2022 | Oct 3, 2020 | $1.20B | Nov 14, 2022 |
| FY2021 | Sep 28, 2019 | $1.26B | Nov 15, 2021 |
| FY2020 | Sep 29, 2018 | $1.20B | Feb 11, 2021 |
| FY2019 | Sep 30, 2017 | $1.07B | Nov 12, 2019 |
| FY2018 | Oct 1, 2016 | $695.00M | Nov 13, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $36.66B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $37.10B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $36.25B | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $36.82B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $36.31B | Nov 13, 2023 |
| FY2022 | Oct 3, 2020 | $34.46B | Nov 14, 2022 |
| FY2020 | Jun 27, 2020 | $34.32B | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | $33.66B | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | $33.56B | Feb 11, 2021 |
| FY2021 | Sep 28, 2019 | $32.92B | Nov 15, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $18.09B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $18.39B | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | $18.13B | Nov 12, 2024 |
| FY2023 | Oct 1, 2022 | $19.70B | Nov 13, 2023 |
| FY2022 | Oct 2, 2021 | $17.72B | Nov 14, 2022 |
| FY2021 | Oct 3, 2020 | $15.25B | Nov 15, 2021 |
| FY2020 | Jun 27, 2020 | $14.69B | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | $14.28B | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | $14.24B | Feb 11, 2021 |
| FY2020 | Sep 28, 2019 | $13.95B | Feb 11, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $9.47B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $9.82B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $9.88B | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $10.51B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $10.55B | Nov 13, 2023 |
| FY2022 | Oct 3, 2020 | $10.90B | Nov 14, 2022 |
| FY2021 | Sep 28, 2019 | $10.84B | Nov 15, 2021 |
| FY2020 | Sep 29, 2018 | $9.74B | Feb 11, 2021 |
| FY2019 | Sep 30, 2017 | $9.32B | Nov 12, 2019 |
| FY2018 | Oct 1, 2016 | $6.67B | Nov 13, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $18.65B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $18.87B | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | $18.76B | Nov 12, 2024 |
| FY2023 | Oct 1, 2022 | $20.08B | Nov 13, 2023 |
| FY2022 | Oct 2, 2021 | $17.50B | Nov 14, 2022 |
| FY2021 | Oct 3, 2020 | $15.10B | Nov 15, 2021 |
| FY2020 | Jun 27, 2020 | $14.60B | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | $14.22B | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | $13.99B | Feb 11, 2021 |
| FY2020 | Sep 28, 2019 | $13.66B | Feb 11, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $1.23B | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $1.72B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $573.00M | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $1.03B | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $2.51B | Nov 13, 2023 |
| FY2022 | Oct 3, 2020 | $1.42B | Nov 14, 2022 |
| FY2021 | Sep 28, 2019 | $484.00M | Nov 15, 2021 |
| FY2020 | Sep 29, 2018 | $270.00M | Feb 11, 2021 |
| FY2019 | Sep 30, 2017 | $318.00M | Nov 12, 2019 |
| FY2019 | Oct 1, 2016 | $349.00M | Nov 12, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | 1 | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | 2 | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | (1) | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | 8 | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | 8 | Nov 13, 2023 |
| FY2020 | Oct 3, 2020 | 1 | Feb 11, 2021 |
| FY2020 | Jun 27, 2020 | 1 | Feb 11, 2021 |
| FY2020 | Mar 28, 2020 | 1 | Feb 11, 2021 |
| FY2020 | Dec 28, 2019 | 1 | Feb 11, 2021 |
| FY2020 | Sep 28, 2019 | 1 | Feb 11, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $697.00M | Nov 10, 2025 |
| FY2025 | Sep 28, 2024 | $684.00M | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $670.00M | Nov 10, 2025 |
| FY2024 | Oct 1, 2022 | $653.00M | Nov 12, 2024 |
| FY2023 | Oct 2, 2021 | $636.00M | Nov 13, 2023 |
| FY2022 | Oct 3, 2020 | $601.00M | Nov 14, 2022 |
| FY2021 | Sep 28, 2019 | $537.00M | Nov 15, 2021 |
| FY2020 | Sep 29, 2018 | $431.00M | Feb 11, 2021 |
| FY2019 | Sep 30, 2017 | $319.00M | Nov 12, 2019 |
| FY2018 | Oct 1, 2016 | $216.00M | Nov 13, 2018 |